Evidence map›Paper›PMID 37724400›Full record

ArticleZhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences2023

RIP3/MLKL regulates necroptosis via activating 4EBP1-eIF4E pathway.

Shuchao Wang, Meili Xu

Open access · greenAbstract read
In one paragraph

Article in Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Shuchao WangCenter for Medical Research, Second Xiangya Hospital, Central South University, Changsha 410011. wangshuchao@csu.edu.cn.
Meili XuDepartment of Gerontology, Second Xiangya Hospital, Central South University, Changsha 410011, China. doctormeili@csu.edu.cn.
Central South University · CN

Funding

the Natural Science Foundation of Changsha, China kq2202388
6 · The paper itself

Abstract

objectivesNecroptosis is a cell death type mediated by receptor interacting protein 3 (RIP3)/mixed lineage kinase domain-like protein (MLKL). It has been reported that mammalian target of rapamycin plays a regulatory role in necroptosis. Eukaryotic translation initiation factor 4E-binding protein 1 (4EBP1)-eukaryotic initiation factor 4E (eIF4E) pathway is a key down streamer of mammalian target of rapamycin. However, whether 4EBP1-eIF4E pathway is involved in necroptosis is still unknown. This study aims to investigate the changes of 4EBP1-eIF4E pathway in necroptosis.

methodsTNF-α/SM-164/Z-VAD-FMK (TSZ), a necroptosis inducer, was used to induce necroptosis in murine fibroblastoid cell line L929. Cell necrosis was observed under an optical microscope. Then, TSZ was added to L929 cells with

resultsAfter treating L929 cells with TSZ, the number of necrotic cells was increased, the mRNA and protein expression levels of

conclusions4EBP1-eIF4E pathway is activated in the RIP3/MLKL mediated-necroptosis.

Indexed as

Eukaryotic Initiation Factor-4ENecroptosisProtein KinasesAnimalsCell LineFluorescenceMiceReceptor-Interacting Protein Serine-Threonine KinasesTOR Serine-Threonine KinasesEukaryotic Initiation Factor-4EMLKL protein, mouseProtein KinasesReceptor-Interacting Protein Serine-Threonine KinasesRipk3 protein, mouseTOR Serine-Threonine Kinaseseukaryotic initiation factor 4Eeukaryotic translation initiation factor 4E-binding protein 1mixed lineage kinase domain-like proteinnecroptosisreceptor interacting protein 3

Identifiers

PMID37724400
PMCPMC10930047
OpenAlexW4386843575

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.